Expert Insights on Novel NMOSD Treatments : Episode 7
Opinion
Video
Complement Inhibitors in NMOSD
Author(s):
Key Takeaways
- Ravulizumab, a complement inhibitor, is FDA-approved for NMOSD, offering a longer half-life than eculizumab, allowing for extended dosing intervals.
- The standard dosing regimen for ravulizumab includes an initial loading dose followed by maintenance doses every eight weeks.
Sean Pittock, MD, discusses how complement inhibitors are positioned in the treatment landscape of neuromyelitis optica spectrum disorder, providing an overview of ravulizumab, the most recent FDA-approved treatment, including its development rationale, half-life, dosing regimen, and new signals from the recently presented 138-week long-term extension data at EAN 2024.
EP: 1.Relapses and Disability Accumulation in NMOSD
EP: 2.Treatments With Higher Efficacy and Relapses in NMOSD
EP: 3.Ravulizumab Long-Term Data and Management of NMOSD
EP: 4.The Evolving Understanding of NMOSD Pathophysiology and the Role of Complement System
EP: 5.Treatment Options to Manage and Prevent Relapses in NMOSD
EP: 6.Importance of Diverse Mechanisms of Action to Effectively Treat NMOSD
Now Viewing
EP: 7.Complement Inhibitors in NMOSD
EP: 8.Meningococcal Infection and NMOSD
Video content above is prompted by the following:
- Where do complement inhibitors fit in the treatment landscape of neuromyelitis optica spectrum disorder (NMOSD)? Which complement inhibitors are approved for NMOSD?
- Please provide an overview of ravulizumab, the most recent FDA-approved treatment for NMOSD, the rationale for its development, half-life, and dosing regimen.
- Long-term extension (138-week) data with ravulizumab were recently presented at EAN 2024.
- Are there any new signals in the long-term extension study?
Related Videos
Related Content
